'%3e%3cpath%20d='M34.1406%205.85938C30.3906%202.10547%2025.3047%200%2020%200C14.6953%200%209.60938%202.10547%205.85938%205.85938C2.10938%209.61328%200%2014.6953%200%2020C0%2025.3047%202.10547%2030.3906%205.85938%2034.1406C9.61328%2037.8906%2014.6953%2040%2020%2040C25.3047%2040%2030.3906%2037.8945%2034.1406%2034.1406C37.8906%2030.3906%2040%2025.3047%2040%2020C40%2014.6953%2037.8945%209.60938%2034.1406%205.85938ZM37.0117%2023.543H31.1602V13.5391H27.6328V19.9414C28.1211%2020.6914%2028.3711%2021.582%2028.3711%2022.5625V22.625C28.3711%2023.668%2028.1172%2024.6055%2027.6328%2025.4297V26.6094H36.082C33.4883%2032.9375%2027.2891%2037.3789%2020.0039%2037.3789C10.3711%2037.3789%202.62109%2029.6289%202.62109%2020C2.62109%2010.3711%2010.3711%202.62109%2020%202.62109C29.6289%202.62109%2037.3789%2010.3711%2037.3789%2020C37.3789%2021.1484%2037.2617%2022.2656%2037.0508%2023.3477C37.0391%2023.4141%2037.0234%2023.4766%2037.0117%2023.543Z'%20fill='white'/%3e%3cpath%20d='M22.3086%2018.5352C20.4336%2018.125%2019.9531%2017.8398%2019.9766%2017.1836V17.1406C19.9766%2016.6992%2020.3477%2016.2148%2021.4023%2016.2148C22.582%2016.2148%2023.8867%2016.6797%2025.0781%2017.4766L26.8516%2015.0195C25.4453%2013.8906%2023.707%2013.3398%2021.5547%2013.3398C18.5195%2013.3398%2016.4375%2015%2016.4063%2017.4766V17.5352C16.3633%2020.2617%2018.5859%2020.9805%2021.293%2021.6016C23.0391%2021.9766%2023.5703%2022.3164%2023.5703%2022.9609L23.5469%2022.9766C23.5469%2023.3906%2023.2578%2023.7031%2022.7852%2023.8359C22.5742%2023.9062%2022.1289%2023.9727%2021.5156%2023.9727C20.7617%2023.9727%2019.7539%2023.8633%2018.6328%2023.4844C18.0898%2023.2891%2017.4727%2023.0039%2016.8047%2022.6133L20.1406%2026.625C20.2813%2026.6602%2021.0977%2026.8516%2021.7734%2026.8516C25.0039%2026.8516%2027.0859%2025.2461%2027.1094%2022.6328V22.5703C27.1602%2020.1133%2025.2148%2019.1719%2022.3086%2018.5352Z'%20fill='white'/%3e%3cpath%20d='M5.24219%2013.5664V26.6133H8.75391V23.7578L10.2969%2021.9531L14.2031%2026.6133H18.3867L12.3555%2019.5195L17.4023%2013.5664H13.4531L8.75391%2019.0586V13.5664H5.24219Z'%20fill='white'/%3e%3c/g%3e%3cdefs%3e%3cclipPath%20id='clip0_97_2430'%3e%3crect%20width='40'%20height='40'%20fill='white'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e)
Lifestyle Features
Most Recent
CVS is trying out pharmacists in chronic health management
Caroline Humer, Reuters | Posted Oct. 23 - 6:40 p.m. | Save Story
Dr. Amy Compton-Phillips on Friday said healthcare affordability and access could potentially improve if pharmacists in its 9,000 retail stores play a bigger role in chronic disease management.
Swiss drug developer Windward Bio files for US IPO
Reuters | Updated Oct. 23 - 3:00 p.m. | Save Story
Windward Bio filed for a US initial public offering on Friday, becoming the latest drug developer seeking to capitalize on renewed investor interest in biotech listings.
US CDC says measles cases rise to 4,588 as outbreak continues
Reuters | Updated Oct. 23 - 11:28 a.m. | Save Story
The US CDC on Friday reported 4,588 measles cases in the country as of October 22, up 178 from a week earlier, as an outbreak of the highly contagious disease continues.
UK approves J&J's oral psoriasis pill
Reuters | Updated Oct. 23 - 10:36 a.m. | Save Story
Britain's medicines regulator on Friday approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy or painful patches.
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
Sahil Pandey, Reuters | Updated Oct. 23 - 10:35 a.m. | Save Story
Zymeworks said on Friday Roche has gained rights to develop and commercialize its experimental lung cancer drug under a global licensing deal worth up to $813 million.
Exclusive-Dr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Rishika Sadam, Reuters | Updated Oct. 23 - 10:27 a.m. | Save Story
Dr Reddy's Laboratories has expanded its portfolio of generic versions of Ozempic with two new brands to fill a supply-chain hit to its original Obeda injections, product photographs and marketing materials reviewed by Reuters show.
Weight-loss drugs fuel protein boom, but with more consumer scrutiny
Waylon Cunningham and Nicholas P. Brown, Reuters | Updated Oct. 23 - 10:25 a.m. | Save Story
Protein-infused bottled water. Ice cream. Boxed macaroni and cheese. Even vodka.
Bristol Myers, SystImmune breast cancer drug cuts progression risk in study
Reuters | Updated Oct. 23 - 6:41 a.m. | Save Story
Bristol Myers Squibb and partner SystImmune said on Friday their experimental breast cancer treatment slowed disease progression compared to standard chemotherapy in a late-stage study.
Dr Reddy's beats quarterly profit estimate on India market lift
Reuters | Updated Oct. 23 - 6:29 a.m. | Save Story
Indian drugmaker Dr Reddy's Laboratories reported a better-than-expected quarterly profit on Friday, as domestic demand helped cushion the slowdown in its key US market.
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
Reuters | Updated Oct. 23 - 5:07 a.m. | Save Story
US biotech company Vor Bio said on Thursday its experimental kidney disease drug slowed the loss of kidney function and reduced the risk of disease progression in a late-stage study.
Explainer-What is Shamonda virus and what are the risks to humans and animals?
Reuters | Updated Oct. 23 - 5:01 a.m. | Save Story
France has reported the first known human case of Shamonda virus in a patient who died, raising questions about the risks posed by a livestock virus that has reached Europe this year decades after first being detected in Nigeria.
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Kamal Choudhury, Reuters | Updated Oct. 23 - 4:39 a.m. | Save Story
Moderna's shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck, triggered what analysts called a "sell-the-news" reaction after a months-long stock surge.
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal
Sahil Pandey, Reuters | Updated Oct. 23 - 4:38 a.m. | Save Story
Gilead Sciences said on Thursday it will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental bowel disease treatment, for $1.275 billion in cash upfront.
Microsoft develops AI tool that can diagnose 'sequentially' like a doctor
Nancy Lapid, Reuters | Updated Oct. 23 - 4:36 a.m. | Save Story
Microsoft researchers say an AI tool that diagnoses patients step by step, as doctors do, was more than twice as accurate as general physicians at solving complex medical cases, according to a study published on Thursday in Science.
Pediatrician warns about energy drink risks for teens
VideoTodd Kunz, KSL | Posted Oct. 22 - 6:35 p.m. | Save Story
Johns Hopkins researchers say nearly a third of teens ages 12 to 17 regularly drink energy drinks, raising concerns about caffeine's effects on young people.
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
Michael Erman and Julie Steenhuysen, Reuters | Updated Oct. 22 - 3:17 p.m. | Save Story
Moderna and Merck said on Thursday that their mRNA cancer vaccine when combined with Merck's widely used immunotherapy cut the risk of melanoma death or recurrence by 42% in a large trial, potentially paving the way for a new era of personalized treatment.
The connection between having in-person friends and problematic social media use
Kara Alaimo, CNN | Posted Oct. 22 - 2:13 p.m. | Save Story
Do you spend too much time on social media? Is it interfering with other parts of your life? New research suggests what could be driving your behavior.
Taco Bell sticks with Pepsi as sister chain switches to Coke
Jordan Valinsky, CNN | Updated Oct. 22 - 2:03 p.m. | Save Story
KFC dumped PepsiCo last week, but its sister chain Taco Bell announced Thursday it's keeping the Mountain Dew Baja Blast maker on for another decade.
